Michael Mina, MD, PhD

Oncology reimbursement has been challenging and eroding over the last several years even while patient numbers are increasing and biomedical innovations are accelerating. Pending CMS proposals for 2025 may increase these challenges, limit provider investments and capabilities, and constrain patient access. Please read our perspective. #concertai #ASCO #oncology https://lnkd.in/eJ6t-GUe

35

Digital health technologies: opportunities & challenges in rheumatology Daniel Solomon, MD MPH & Bob Rudin, PhD Abstract The past decade in rheumatology has seen tremendous innovation in digital health technologies, including the electronic health record, virtual visits, mobile health, wearable technology, digital therapeutics, artificial intelligence and machine learning. The increased availability of these technologies offers opportunities for improving important aspects of rheumatology, including access, outcomes, adherence and research. However, despite its growth in some areas, particularly with non-health-care consumers, digital health technology has not substantially changed the delivery of rheumatology care. This Review discusses key barriers and opportunities to improve application of digital health in rheumatology. Key topics include smart design, voice enablement and the integration of electronic patient-reported outcomes. Smart design involves active engagement with the end users of the technologies, including patients and clinicians through focus groups, user testing sessions and prototype review. Voice enablement using voice assistants could be critical for enabling patients with hand arthritis to effectively use smartphone apps and might facilitate patient engagement with many technologies. Tracking many rheumatic diseases requires frequent monitoring of #patientreportedoutcomes. Current practice only collects this information sporadically, and rarely between visits. #Digitalhealth technology could enable patient-reported outcomes to inform appropriate timing of face-to-face visits and enable improved application of treat-to-target strategies. However, best practice standards for digital health technologies do not yet exist. To achieve the potential of digital health technology in rheumatology, rheumatology professionals will need to be more engaged in the technology design process and provide leadership to effectively incorporate new tools into clinical care. Key points Digital health technology (DHT) offers enormous potential to improve rheumatology care but this potential has so far been largely unrealized. The #electronichealthrecord, virtual visits, mobile health, wearable technology, digital therapeutics, artificial intelligence and machine learning could all have a role individually and in combination to reshape rheumatology practice. Increased use of user-centred design in the development of #digitalrheumatology tools is needed and will facilitate electronic patient-reported outcomes becoming a cornerstone of rheumatology. https://lnkd.in/eEZCSEg7

3

1 Comment

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

This is super interesting, Roche wants to spin out Flatiron Health, which it bought for $2B back in 2018. The vision was that Flatiron's onco real world evidence would accelerate Roche drug development, but I guess this means that didn't go as planned? And/or perhaps the success of the Tempus AI IPO is making onco data asset valuations look pretty nice - though seems like a few billion from sale would drop in the bucket for Roche compared to helping with drug dev 🤔🤔🤔 Background from the FT: "Flatiron manages electronic patient records for a sprawling network of cancer clinics in the US, giving the start-up access to one of the biggest repositories of data on the disease. Founded by two former Google executives, Flatiron then mines the data and sells it to pharmaceutical groups, which use it to inform their research and development efforts." "Although Roche has kept Flatiron as a separate legal entity, its ownership has deterred some rival drugmakers from doing business with the start-up and hurt sales, according to two people familiar with the matter. Flatiron generates about two-thirds of its revenues selling data to pharmaceutical companies."

183

25 Comments